Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age ( ≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: Results of the FAB LMB 96 study

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 387-393

  Cairo, Mitchell S ^a   Sposto, Richard ^b   Gerrard, Mary ^c   Auperin, Anne ^f   Goldman, Stanton C ^h   Harrison, Lauren ^a   Pinkerton, Ross ^d   Raphael, Martine ^g   McCarthy, Keith ^e   Perkins, Sherrie L ⁱ   Patte, Catherine ^f  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g BICÊTRE HOSPITAL   (France)

^h Medical City Children's Hospital   (United States)

ⁱ UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGE FACTORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL; MALE; NEOPLASM STAGING; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856707833     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.3369     Document Type: Article

References (38)

1. Cairo MS, Raetz E, Perkins SL: Non-Hodgkin's lymphoma in children, in Kufe DW, Bast RC, Hait WN, et al (eds): Cancer Medicine (ed 7). Hamilton, Ontario, Canada, BC Decker, 2005, pp 1962-1976
2. Perkins SL, Segal GH, Kjeldsberg CR: Classification of non-Hodgkin's lymphomas in children. Semin Diagn Pathol 12:303-313, 1995
3. Atra A, Imeson JD, Hobson R, et al: Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): Results of the United Kingdom Children's Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82:1396-1402, 2000 (Pubitemid 30175904)
4. Bowman WP, Shuster JJ, Cook B, et al: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A pediatric oncology group study. J Clin Oncol 14:1252-1261, 1996 (Pubitemid 26105533)
5. Brecher ML, Schwenn MR, Coppes MJ, et al: Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCL): A randomized trial of the Pediatric Oncology Group. Med Pediatr Oncol 29:526-533, 1997 (Pubitemid 27419403)
6. Cairo MS, Gerrard M, Sposto R, et al: Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109:2736-2743, 2007 (Pubitemid 46482065)
7. Cairo MS, Krailo MD, Morse M, et al: Longterm follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: A Children's Cancer Group report. Leukemia 16:594-600, 2002 (Pubitemid 34449739)
8. Cairo MS, Sposto R, Hoover-Regan M, et al: Childhood and adolescent large-cell lymphoma (LCL): A review of the Children's Cancer Group experience. Am J Hematol 72:53-63, 2003 (Pubitemid 36043751)
9. Cairo MS, Sposto R, Perkins SL, et al: Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol 120:660-670, 2003 (Pubitemid 36255868)
10. Gerrard M, Cairo MS, Weston C, et al: Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: Results of the FAB/LMB 96 international study. Br J Haematol 141:840-847, 2008 (Pubitemid 351724873)
11. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996 (Pubitemid 26085538)
12. Patte C, Auperin A, Gerrard M, et al: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 109:2773-2780, 2007 (Pubitemid 46482070)
13. Patte C, Auperin A, Michon J, et al: The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370-3379, 2001
14. Reiter A, Schrappe M, Tiemann M, et al: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94:3294-3306, 1999 (Pubitemid 29536122)
15. Spreafico F, Massimino M, Luksch R, et al: Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol 20:2783-2788, 2002 (Pubitemid 34651506)
16. Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948-958, 2005 (Pubitemid 40170860)
17. Bleyer WA, O'Leary M, Barr R, et al (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15-29 Years of Age, Including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH publication 06-5767. Bethesda, MD, 2006
18. Anderson JR, Jenkin RD, Wilson JF, et al: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Children's Cancer Group. J Clin Oncol 11:1024-1032, 1993 (Pubitemid 23163340)
19. Anderson JR, Wilson JF, Jenkin DT, et al: Childhood non-Hodgkin's lymphoma: The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559-565, 1983 (Pubitemid 13142000)
20. Cairo MS: Treatment and outcome in adolescents and young adults (AYA) with intermediate and aggressive non-Hodgkin's Lymphoma (NHL). Ann Oncol 16:v41, 2005 (abstr 035)
21. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994 (Pubitemid 24273002)
22. Murphy SB: Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980
23. Lones MA, Perkins SL, Sposto R, et al: Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: A Children's Cancer Group report. J Clin Oncol 18:3845-3853, 2000
24. Miles RR, Raphael M, McCarthy K, et al: Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) International Study Group. Pediatr Blood Cancer 51:369-374, 2008
25. Percy CL, Smith MA, Linet M, et al: Lymphomas and reticuloendothelial neoplasms, in Ries LAG, Smith MA, Gurney JG, et al (eds): Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD, National Cancer Institute, Seer Program, 1999, pp 35-50
26. Burkhardt B, Zimmermann M, Oschlies I, et al: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39-49, 2005 (Pubitemid 43899706)
27. Hochberg J, Waxman IM, Kelly KM, et al: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: State of the science. Br J Haematol 144:24-40, 2009
28. Albritton K, Bleyer WA: The management of cancer in the older adolescent. Eur J Cancer 39: 2584-2599, 2003 (Pubitemid 37468300)
29. Patte C, Bleyer WA, Cairo MS: Non-Hodgkin lymphoma, in Bleyer A, Barr R (eds): Cancer in Adolescents and Young Adults. Heidelberg, Germany, Springer-Verlag, 2008, pp 127-151
30. Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003 (Pubitemid 37152922)
31. Feuerhake F, Kutok JL, Monti S, et al: NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106: 1392-1399, 2005 (Pubitemid 41129606)
32. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003 (Pubitemid 37486965)
33. Cairo MS, Lynch J, Harrison L, et al: Safety, efficacy and rituximab levels following chemoimmunotherapy (rituximab + FAB chemotherapy) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report. Blood 112:838a, 2008 (abstr 838)
34. Cairo MS, Lynch JC, Harrison L, et al: Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group Report. J Clin Oncol 28:687s, 2010 (suppl; abstr 9536)
35. Pillon M, Di Tullio MT, Garaventa A, et al: Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 101:385-394, 2004 (Pubitemid 38890844)
36. Mussolin L, Pillon M, Conter V, et al: Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol 25:5254-5261, 2007 (Pubitemid 350232258)
37. Meinhardt A, Burkhardt B, Zimmermann M, et al: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 28:3115-3121, 2010
38. Poirel HA, Cairo MS, Heerema NA, et al: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: Results of the FAB/LMB 96 international study. Leukemia 23:323-331, 2009